Icosavax to Participate in the Upcoming Healthcare Conferences
28 févr. 2023 08h00 HE
|
Icosavax, Inc.
SEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
22 févr. 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV Data from the single ascending dose part of the Phase 1 trial...
Icosavax Granted FDA Fast Track Designation for IVX-A12
21 févr. 2023 08h00 HE
|
Icosavax, Inc.
SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
23 janv. 2023 18h30 HE
|
Novartis Pharma AG
Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly...
Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing
11 janv. 2023 02h00 HE
|
Valo Therapeutics LTD
HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it...
Icosavax Provides Corporate Update and Anticipated Milestones for 2023
06 janv. 2023 08h00 HE
|
Icosavax, Inc.
- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company’s VLP platform - - Phase 1 study of...
IMUNON Enters into Collaborative Research Agreement with The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform
05 janv. 2023 08h30 HE
|
Imunon, Inc.
LAWRENCEVILLE, NJ and PHILADELPHIA, PA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, and The Wistar Institute, a global leader in...
IBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.
13 déc. 2022 08h17 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to...
Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023
12 déc. 2022 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s Board of Directors (Board) has decided to not undertake the reverse stock split and...
BiondVax Regains Nasdaq Compliance
12 déc. 2022 07h06 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 12, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...